Efficacy of intralesional MMR vaccine in treatment of single or multiple refractory cutaneous warts

Mohd Mohtashim; Syed Suhail Amin; Mohammad Adil; Tasleem Arif; Manu Singh; Roopal Bansal; Dinesh Raj

doi:10.5114/dr.2018.78071

Immunotherapy in cutaneous warts: comparative clinical Study between MMR vaccine, tuberculin, and BCG Vaccine

Journal of Cosmetic Dermatology ◽

10.1111/jocd.13921 ◽

2021 ◽

Author(s):

Engi Seif E. Shaker ◽

Noha N. Doghim ◽

Arwa Mhammad Hassan ◽

Samia S. Musafa ◽

Mohamed M. Fawzy

Keyword(s):

Clinical Study ◽

Bcg Vaccine ◽

Mmr Vaccine ◽

Comparative Clinical Study ◽

Cutaneous Warts

Download Full-text

Effectiveness of measles, mumps and rubella vaccine as immunotherapeutic agent for cutaneous viral warts

International Journal of Research in Dermatology ◽

10.18203/issn.2455-4529.intjresdermatol20201598 ◽

2020 ◽

Vol 6 (3) ◽

pp. 439

Author(s):

Anupama Devi Wahengbam ◽

Jeyakumari Jeevan ◽

Sowmya Dogiparthi

Keyword(s):

Clinical Studies ◽

Single Agent ◽

Complete Response ◽

Mmr Vaccine ◽

Rubella Vaccine ◽

Immunotherapeutic Agent ◽

Management Evaluation ◽

Cutaneous Wart ◽

Short Narrative ◽

Cutaneous Warts

Immunotherapy for management of cutaneous wart with measles, mumps and rubella vaccine (MMR) is a promising new modality of management. Evaluation of the same has been done by various studies over the years reporting its effectiveness. A literature search was done using PubMed and google scholar. This short narrative review documents the response rates in various clinical studies done till 2019 which have reported the efficacy of MMR vaccine as an immunotherapeutic agent which ranged from 26-84% graded as complete response which is complete clearance of the treated warts. These studies were performed for evaluating MMR vaccine as single agent or done in comparison with other therapeutic agents. The broad range of responses points to a need of doing further clinical studies which will substantiate the effectiveness of MMR vaccine in the treatment of cutaneous warts.

Download Full-text

A randomized comparative study of MIP and MMR vaccine for the treatment of cutaneous warts

Indian Journal of Dermatology ◽

10.4103/ijd.ijd_700_20 ◽

2021 ◽

Vol 66 (2) ◽

pp. 151

Author(s):

Amandeep Kaur ◽

BalvinderKaur Brar ◽

Sumir Kumar ◽

SukhmaniKaur Brar ◽

AmarbirSingh Boparai ◽

...

Keyword(s):

Comparative Study ◽

Mmr Vaccine ◽

Cutaneous Warts

Download Full-text

Intralesional Measles, Mumps, and Rubella Vaccine for Cutaneous Warts: A Systematic Review and Meta-analysis

Acta Medica Philippina ◽

10.47895/amp.v53i2.211 ◽

2019 ◽

Vol 53 (2) ◽

Author(s):

Patricia A. Nacianceno ◽

Marie Len A. Camaclang ◽

Francisca DC. Roa

Keyword(s):

Risk Ratio ◽

Meta Analysis ◽

P Value ◽

Cell Mediated Immunity ◽

Mmr Vaccine ◽

Papilloma Virus ◽

Online Databases ◽

Significant Difference ◽

Cutaneous Warts

Background. Warts, caused by the human papilloma virus (HPV), are mucocutaneous proliferations controlled by cell-mediated immunity. Intralesional immunotherapy with measles, mumps, and rubella (MMR) vaccine, is postulated to induce a higher immune response for clearance of lesions. Objective. To assess the efficacy, safety and effect on recurrence of intralesional MMR vaccine for the treatment of warts. Methods. We searched online databases for randomized controlled trials on intralesional MMR vaccine for warts. Effects measured were the complete clearance of target and distant warts, adverse events noted and recurrence after treatment duration. Results. Four RCTs comparing intralesional MMR vaccine and placebo were assessed. Meta-analysis showed a risk ratio of 0.24 [95% CI: 0.18, 0.34] favoring intralesional MMR vaccine and a highly significant difference in completely clearing target warts (P-value <0.00001) versus placebo. Three of the 4 trials assessed response of distant warts showing a risk ratio of 0.28 [95% CI: 0.08, 0.96] and a significant difference (P=0.04) versus placebo. Pain and flu-like symptoms were the most common side effects with no recurrence seen after 3-6 months. Conclusions. Intralesional MMR vaccine significantly reduces and clears target and distant warts as compared to placebo. It is a generally safe intervention with lasting effect assessed up to 6 months follow-up.

Download Full-text

Comparison of cryotherapy versus intralesional measles, mumps, rubella vaccine versus their combination therapy in Indian patients with cutaneous wart: a single centre prospective observational study

International Journal of Research in Dermatology ◽

10.18203/issn.2455-4529.intjresdermatol20193852 ◽

2019 ◽

Vol 5 (4) ◽

pp. 715

Author(s):

Mithila Uday Vanarase

Keyword(s):

Observational Study ◽

Group Treatment ◽

Prospective Observational Study ◽

Intralesional Injection ◽

Mmr Vaccine ◽

Indian Patients ◽

Cutaneous Wart ◽

Group A ◽

Group B ◽

Cutaneous Warts

Background: Need for more effective and less time consuming therapeutic method is current necessity for treatment of cutaneous warts. The objective of the study was to evaluate and compare the efficacy, safety of cryotherapy versus intralesional measles, mumps, rubella (MMR) vaccine versus combination of cryotherapy and intralesional MMR vaccine in Indian patients with cutaneous wart.Methods: This prospective observational study was conducted in 60 patients of cutaneous warts. Patients were divided into three groups viz., group A, group B and group C. Group A was treated with cryotherapy alone, Group B received intralesional injection 0.1 to 0.3 ml of MMR vaccine alone and Group C received combination of group A and group B therapy. In each group treatment was repeated at 3 week interval for a maximum of 4 sittings. Percentage of improvement was evaluated using visual analogue scale (VAS) for local as well as distant (non-inoculated) warts. Follow-up was made every 2 months till 4 months to detect any recurrence.Results: For local warts in second half of treatment (12th week) patients of Group B and Group C showed significantly better response than patients in Group A. For distant warts in first half of treatment session patients showed significantly better response to Group C than as compared to Group B therapy (p<0.039).Conclusions: Immunotherapy with MMR is superior treatment than cryotherapy for cutaneous warts with minimum side effects but the combination of cryotherapy with intralesional MMR has shown to have complementary effect in treatment response.

Download Full-text